Cancer is a multistep process that involves mutations and other alterations in oncogenes and tumour suppressor genes 1 . Genome sequencing studies have identified a large collection of genetic alterations that occur in human cancers [2] [3] [4] . However, the determination of which mutations are causally related to tumorigenesis remains a major challenge. Here we describe a novel CRISPR/Cas9-based approach for rapid functional investigation of candidate genes in well-established autochthonous mouse models of cancer. Using a Kras G12D -driven lung cancer model 5 , we performed functional characterization of a panel of tumour suppressor genes with known loss-of-function alterations in human lung cancer. Cre-dependent somatic activation of oncogenic Kras G12D combined with CRISPR/Cas9-mediated genome editing of tumour suppressor genes resulted in lung adenocarcinomas with distinct histopathological and molecular features. This rapid somatic genome engineering approach enables functional characterization of putative cancer genes in the lung and other tissues using autochthonous mouse models. We anticipate that this approach can be used to systematically dissect the complex catalogue of mutations identified in cancer genome sequencing studies.
Cancer is a multistep process that involves mutations and other alterations in oncogenes and tumour suppressor genes 1 . Genome sequencing studies have identified a large collection of genetic alterations that occur in human cancers [2] [3] [4] . However, the determination of which mutations are causally related to tumorigenesis remains a major challenge. Here we describe a novel CRISPR/Cas9-based approach for rapid functional investigation of candidate genes in well-established autochthonous mouse models of cancer. Using a Kras G12D -driven lung cancer model 5 , we performed functional characterization of a panel of tumour suppressor genes with known loss-of-function alterations in human lung cancer. Cre-dependent somatic activation of oncogenic Kras G12D combined with CRISPR/Cas9-mediated genome editing of tumour suppressor genes resulted in lung adenocarcinomas with distinct histopathological and molecular features. This rapid somatic genome engineering approach enables functional characterization of putative cancer genes in the lung and other tissues using autochthonous mouse models. We anticipate that this approach can be used to systematically dissect the complex catalogue of mutations identified in cancer genome sequencing studies.
Lung cancer genome sequencing studies have revealed a multitude of recurrent mutations and copy number alterations [2] [3] [4] . However, the determination of which mutations are causally related to tumorigenesis remains a major challenge. Genetically engineered mouse models of lung cancer have assisted in the functional characterization of putative driver events identified in human lung tumours 6, 7 , but these require modification of the germ line and cannot be performed in a highly parallel manner.
Recent work from our laboratory has demonstrated the feasibility of using the CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 system to directly mutate cancer genes in the liver following hydrodynamic delivery of plasmids carrying the CRISPR components 8 , which relies on the efficient transfection of hepatocytes. To rapidly interrogate cancer genes in the lung and other tissues, we developed pSECC (Fig. 1a) , a lentiviral-based system that delivers both the CRISPR system and Cre recombinase. In this setting, CRISPR-induced mutation of genes can be examined in the context of several of the wellstudied conditional Cre/loxP mouse models of lung cancer 9 and other cancer types. To test this system, we used genetically engineered mouse models of lung adenocarcinoma, in which tumours are induced in loxP-Stop-loxP Kras G12D/1 (hereafter referred to as Kras LSL-G12D/1 ) or Kras LSL-G12D/1 ; p53 fl/fl mice upon intratracheal administration of lentiviral vectors expressing Cre recombinase 10, 11 .
To validate pSECC, we developed the Green-Go (GG) reporter cell line, which expresses GFP following exposure to Cre (Extended Data Fig. 1a -c). To assess the efficiency of Cas9 in tumours in vivo, we targeted a Cre-activatable tdTomato knock-in reporter allele 12 with pSECC lentiviruses expressing a single guide RNA (sgRNA) against tdTomato (sgTom) or an empty vector control (Extended Data Fig. 1d, e ). At 10 weeks post-infection, we assessed knockdown of tdTomato expression by immunohistochemistry. We observed that 28% of tumours lacked tdTomato expression, suggesting that the system was functional in vivo by editing an endogenous allele in the context of a lung tumour (Extended Data Fig. 2a-e ). Importantly, animals infected with empty pSECC rarely contained non-tumour Tomato-expressing cells (data not shown), indicating that there is minimal infection of non-epithelial cells when using a low lentiviral titre.
We then proceeded to functionally characterize tumour suppressor genes using this approach. Loss of NK2 homeobox 1 (Nkx2-1), a master regulator of lung development 13 , or phosphatase and tensin homologue (Pten), a negative regulator of oncogenic PI(3)K/Akt signalling 14 accelerates lung tumorigenesis in Kras LSL-G12D/1 and Kras LSL-G12D/1 ; p53 fl/fl lung tumour models 10, 15, 16 . We infected Kras LSL-G12D/1 and Kras LSL-G12D/1 ; p53 fl/fl animals with pSECC vectors expressing validated sgPten, sgNkx2-1 and controls (sgTom and empty vector) to induce lung tumours. Ten weeks post-infection, we euthanized animals to assess the effects of CRISPR/Cas9-mediated gene editing in tumours by histopathology, surveyor assays and deep sequencing of the targeted alleles ( Fig. 1a ). All animals expressing sgRNAs targeting Pten or Nkx2-1 contained tumours with marked histopathological differences compared to controls (Fig. 1b, d and Extended Data Fig. 3a-d ).
Animals infected with sgNkx2-1-pSECC developed mucinous adenocarcinomas typified by the presence of elongated cells, mucin production and glandular rearrangements, in agreement with previous Cre/ loxP-based (Nkx2-1 fl/fl ) data 16 (Fig. 1b ). The majority of tumours (61%, 54/88 tumours) from sgNkx2-1-pSECC animals lacked Nkx2-1 expression (compared to 0/33 tumours from controls) ( Fig. 1b, c) . Importantly, 85% (46/54 tumours) of these Nkx2-1-negative tumours stained positively for mucin ( Fig. 1c ), a biomarker of mucinous adenocarcinomas 16 . Thus, although a subset of tumours appeared to partially or fully escape CRISPR-mediated deletion of Nkx2-1, we were able to observe clear phenotypes by examining the full spectrum of tumours generated by sgNkx2-1-pSECC.
Animals infected with sgPten-pSECC demonstrated complete loss of Pten protein in 74% of tumours (40/54 tumours), which was accompanied by a concomitant increase in pAkt (S473), a downstream biomarker of increased PI(3)-kinase pathway activity ( Fig. 1d, e ). These results mimic previously published data using a Pten fl/fl allele in Kras LSL-G12D/1 mice 15 . Collectively, these data indicate that CRISPR/ Cas9-based gene editing leads to loss-of-function mutations in this model and closely parallels what is seen with the use of traditional conditional alleles.
We next used this system to study adenomatous polyposis coli (Apc), a tumour suppressor whose functional role in lung adenocarcinoma has not been characterized. Of note, Apc is found in a region that frequently undergoes copy number loss in human lung cancer 4 . We infected animals with pSECC lentiviruses expressing a validated sgRNA 17 targeting Apc. At 10 weeks post-infection, we observed a striking difference in the histopathology of sgApc tumours compared to controls ( Fig. 1f and Extended Data Fig. 3e ). Importantly, tumours from Kras LSL-G12D/1 ; Apc fl/fl mice, which express a conditional allele of Apc 18 , exhibited identical histopathology ( Fig. 1f ). Tumours with Cas9-mediated deletion of Apc were highly dedifferentiated, invasive and had a significant stromal component ( Fig. 1f ). The majority of these tumours (78%, 91/117) stained strongly for nuclear b-catenin, a marker of Apc mutation in colon cancer and other settings 19 (Fig. 1f, g ). Furthermore, 77% (70/91) of tumours with nuclear b-catenin stained positive for the transcription factor Sox9, which might reflect a distal embryonic differentiation state 20, 21 . Of note, we observed a statistically significantly higher number of Sox9-positive tumours in Kras LSL-G12D/1 ; p53 fl/fl -sgApc (29/33, or 88%) than in Kras LSL-G12D/1 -sgApc mice (41/58 tumours, or 71%), suggesting a possible role for p53 in regulating this change in differentiation (Extended Data Fig. 6b , c).
To further characterize the differentiation state of sgApc tumours, we stained serial sections for lung differentiation markers, including Sox2, Clara cell secretory protein (CCSP), surfactant protein C (SP-C), p63, Nkx2-1 and Sox9 (Extended Data Fig. 6a ) 22 . Tumours from Kras LSL-G12D/1 ; p53 fl/fl -sgTom mice stained positively for CCSP, SP-C and Nkx2-1 and negatively for Sox2, p63 and Sox9. In contrast, tumours 
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from sgApc mice frequently stained positively for SP-C, Nkx2-1 and Sox9 and negatively for CCSP, Sox2 and p63. A large number of tumours from sgApc mice had areas with low levels or complete absence of Nkx2-1, which correlated with the levels of the Nkx2-1 transcriptional target SP-C 22 (16/52 tumours, or 31%) (Extended Data Fig. 6d ).
These data indicate that these tumours are poorly differentiated and that hyperactivation of the canonical Wnt signalling pathway through loss of Apc in Kras-driven lung adenocarcinomas results in tumours with varying degrees of differentiation. These results also mimic what we observed in tumours from Apc conditional knockout mice ( Fig. 1f and Extended Data Fig. 6e ) and recapitulate recent observations in a Braf V600E -driven mouse model of lung adenocarcinoma upon Wnt pathway hyperactivation 23 .
Our initial analysis demonstrated histological and pathway-specific differences upon deletion of these tumour suppressors in lung tumours. To assess the overall impact of these alterations on tumorigenesis, we measured tumour burden and grade in both Kras LSL-G12D/1 and Kras LSL-G12D/1 ; p53 fl/fl animals. Deletion of Pten and Apc significantly increased overall tumour burden, which correlated with higher tumour grades (Grade 3 and 4) ( Fig. 2a -c and Extended Data Fig. 3f , g). Nkx2-1 deletion had a significant effect on overall tumour burden only in Kras LSL-G12D/1 ; p53 fl/fl animals; however, we observed a striking transition to highly dedifferentiated mucinous adenocarcinoma tumours in both Kras LSL-G12D/1 and Kras LSL-G12D/1 ; p53 fl/fl mice ( Fig. 2a -c, Extended Data Fig. 3f , g and Extended Data Fig. 4a-d ). Conversely, Apc deletion had a significant effect on tumour burden only in Kras LSL-G12D/1 mice ( Fig. 2a and Extended Data Fig. 3f , g). Deletion of all three genes led to increased BrdU incorporation, suggesting that the increased tumour burden is partly due to increased proliferation (Extended Data Fig. 3h ). These data demonstrate the tumour suppressive role of Nkx2-1, Pten and Apc in the context of oncogenic Kras. Furthermore, the unique histopathology observed for each targeted tumour suppressor gene in this Kras-driven model illustrates the potential of this approach to rapidly model the effects of cooperative genetic events in lung tumorigenesis and progression.
Using this in vivo somatic genome editing approach, we observed inter-and intra-tumoral heterogeneity in terms of CRISPR-based lossof-function of Pten in sgPten animals (Fig. 2d , e and Extended Data Fig. 5 ). Clones that acquired loss of Pten had increased PI(3)K/Akt signalling and may, therefore, have had a selective advantage over tumours that retained wild-type Pten within the same animal. We observed that tumours with complete or sub-clonal loss of Pten were significantly larger than tumours that retained Pten (Fig. 2d, e ).
The histopathological and immunohistochemistry analyses indicate that the pSECC system is highly efficient in vivo, leading to robust target-specific phenotypic differences in lung tumours. To confirm Cas9mediated editing of the alleles and precisely characterize the events at single-nucleotide resolution, we performed deep sequencing of target loci from whole lung and tumour DNA. Within a 23 base pair (bp) window (6 10 bp flanking the protospacer adjacent motif (PAM) sequence at each locus), the rate of mutations observed in the sgTarget samples was significantly greater than in the control samples ( Fig. 3a-c) . Using the control samples as a background model to analyse the mutational rate revealed that sgTarget samples were enriched for mutations within 7 bp upstream of the PAM sequences in predicted cutting sites, strongly suggesting that they are not secondary consequences of tumour progression ( Fig. 3d and Extended Data Fig. 7a-c) . The maximum per-base mutation frequency observed in sgTarget samples was 71.7% in Nkx2-1, 66.06% in Pten and 39.91% in Apc (in contrast to control samples: 0.11%, 0.73% and 0.14%, respectively). On average, 27.48% 6 10.3 (Nkx2-1), 44.64% 6 5.3 (Pten) and 13.54% 6 5.3 (Apc) read fragments covering this 7 bp locus harboured indels in sgTarget samples. Across all sgTarget samples, . 94% of observed indels constituted non-synonymous framealtering events (Extended Data Fig. 7d, e and Supplementary Tables 3  and 4 ).
Several studies have reported that Cas9 can bind to sites in the genome other than the intended target site [24] [25] [26] [27] , which could result in unintended editing at an off-target (OT) site. To assess off-target editing, we analysed the top three predicted 24 loci (Supplementary Tables 2) for each sgRNA by deep sequencing. We observed negligible off-target editing (Extended Data Fig. 8 ). On average, 0.048% 6 0.031 (for sgNkx2-1), 0.26% 6 0.096 (for sgPten) and 0.051% 6 0.027 (for sgApc) of read fragments harboured indels in the off-target sites ( Supplementary Tables 5-7 ). This data suggests that the observations reported for each of the sgRNAs arise from deletion of the intended target and not from editing of another gene.
The goal of cancer genomics is to identify genetic events that underlie cancer initiation and progression. The functional interrogation of 7) ), sgNkx2-1 (Kras LSL-G12D/1 (n 5 2) and Kras LSL-G12D/1 ; p53 fl/fl (n 5 6)), sgApc (Kras LSL-G12D/1 (n 5 3) and Kras LSL-G12D/1 ; p53 fl/fl (n 5 6)) and sgPten (Kras LSL-G12D/1 (n 5 4 ) and Kras LSL-G12D/1 ; p53 fl/fl (n 5 3)). G1, grade 1; G2, grade 2; G3, grade 3; G4, grade 4; MA, mucinous adenocarcinoma. d, Distribution of Pten IHC staining status in all sgPten-pSECC infected animals (n 5 9) represented as percent of negative, mixed and positive tumours. e, Quantification of average tumour area (mm 2 ) of tumours staining negative, mixed or positive in all sgPten-pSECC infected animals (n 5 9). Positive tumour, ,100% of the tumour cells stained positive for Pten. Mixed tumour, at least ,30% of tumour cells stained positive for Pten. Negative tumour, , 25% of the tumour cells stained positive for Pten. NS, not significant, *P , 0.05, **P , 0.01, ***P , 0.001 obtained from two-sided Student's t-test. All error bars denote s.e.m.
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putative cancer genes in appropriate experimental models will elucidate which mutations identify bona fide cancer genes. This study presents a novel approach to rapidly evaluate human cancer genome candidates and assess cooperativity between genetic events in the context of wellestablished mouse models of lung cancer. Moreover, our ability to model different lung adenocarcinoma subtypes allows for the detailed study of subtype-specific molecular mechanisms controlling disease initiation and progression. We anticipate that this approach can be readily adapted to many existing Cre/loxP-based genetically engineered mouse models of several cancer types to facilitate the rapid functional assessment of new hypotheses generated by cancer genome studies.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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METHODS Lentiviral vectors and sgRNA cloning. The U6-sgRNA-EFS-Cas9-2A-Cre (pSECC) lentiviral vector was constructed by assembling four parts with overlapping DNA ends using Gibson assembly. Briefly, a 2.2 kb part (corresponding to the U6-Filler fragment from LentiCRISPR 28 ), a 0.3 kb part (corresponding to the EFS promoter from LentiCRISPR 28 ), a 5.3 kb part (corresponding to a Cas9-2A-Cre fragment, which was generated by assembly PCR) and a 5.7 kb lentiviral backbone were assembled using Gibson assembly following manufacturer guidelines. Detailed cloning strategies and primer sequences are available on request. For sgRNA cloning, the pSECC vector was digested with BsmBI and ligated with BsmBI-compatible annealed oligos ( Supplementary Table 1 ). sgRNAs were designed using CRISPR Design 24 (which was also used to predict potential off-target sites; see Extended Data Fig. 8 and Supplementary Table 2 ) or E-CRISP 29 , except for sgApc which was previously reported 17 . An extra G (required for U6 transcriptional initiation) was added to the 59 end of sgRNAs that lacked it. The pSECC lentiviral vector is available through Addgene. Lentiviral production. Lentiviruses were produced by co-transfection of 293T cells with lentiviral backbone constructs and packaging vectors (delta8.2 and VSV-G) using TransIT-LT1 (Mirus Bio). Supernatant was collected 48 and 72 h posttransfection, concentrated by ultracentrifugation at 25,000 r.p.m. for 90 min and resuspended in an appropriate volume of OptiMEM (Gibco).
Cell culture and generation of Green-Go cells. Cells were maintained in DMEM supplemented with 10% fetal bovine serum and gentamicin. Green-Go cells were generated by transducing 3TZ cells 30 with a bicistronic retrovirus containing an LTR promoter-driven inverted GFP (flanked by two sets of incompatible loxP sites) and a PGK-driven puromycin resistance cassette. Transduced cells were selected with puromycin and a single cell clone that expressed high levels of GFP 2-3 days after infection with a lentivirus expressing Cre recombinase was chosen.
Immunobloting. Cells were lysed with ice-cold RIPA buffer (Pierce, #89900) supplemented with 1 3 Complete Mini inhibitor mixture (Roche, #11 836 153 001) and mixed on a rotator at 4 uC for 30 min. Protein concentration of the cell lysates was quantified using the Bio-Rad DC Protein Assay (Catalogue #500-0114). Then 50-80 mg of total protein was separated on 4-12% Bis-Tris gradient gels (Life Technologies) by SDS-PAGE and then transferred to nitrocellulose membranes.
The following antibodies were used for immunoblotting: anti-Flag (Sigma, F1804, 1:1,000), anti-Hsp90 (BD, #610418, 1:10,000), anti-Pten (Cell Signaling, 9188, 1:1,000), anti-TTF1 / Nkx2-1 (Epitomics, EP1584Y, 1:1,000).
Mice. All animal studies described in this study were approved by the MIT Institutional Animal Care and Use Committee. All animals were maintained on a mixed C57BL/6J 3 129SvJ genetic background. Kras LSL-G12D/1 and p53 fl/fl mice have already been described 5, 31 . Mice were infected intratracheally with lentiviruses as described 32 . We infected a total of 7 mice with Empty-pSECC and 6 mice with sgTom-pSECC (for a total of 13 control mice), as well as 8 mice with sgNkx2-1-pSECC, 9 mice with sgPten-pSECC and 9 mice with sgApc-pSECC. No randomization or blinding was used. Total lung area occupied by tumour was measured on haematoxylin and eosin (H&E) stained slides using NIS-elements software.
Immunohistochemistry. Mice were euthanized by carbon dioxide asphyxiation. Lungs were perfused through the trachea with 4% paraformaldehyde (PFA), fixed overnight, transferred to 70% ethanol and subsequently embedded in paraffin. Sections were cut at a thickness of 4 mm and stained with H&E for pathological examination. Immunohistochemistry (IHC) was performed on a Thermo Autostainer 360 machine. Slides were antigen retrieved using Thermo citrate buffer, pH 6.0 in the pre-treatment module. Sections were treated with Biocare rodent block, primary antibody, and anti-mouse (Biocare) or anti-rabbit (Vector Labs) HRP-polymer. The slides were developed with Thermo Ultra DAB and counterstained with haematoxylin in a Thermo Gemini stainer and coverslips added using the Thermo Consul cover slipper. The following antibodies were used for IHC: anti-TTF1 / Nkx2- Deep sequencing and bioinformatic analysis of Cas9 target loci. For each target gene or potential off-target site, a genomic region containing the target sequence was amplified using Herculase II Fusion DNA polymerase and gel purified (primer sequences are shown in Supplementary Table 1 ). Sequencing libraries were prepared from 50 ng of PCR product using the Nextera DNA Sample Preparation Kit (Illumina) and sequenced on Illumina MiSeq machines. In order to retain highquality sequence for mutation analysis, Illumina MiSeq reads (150 bp paired-end) were trimmed to 100mer paired end reads to drop lower quality 39 ends of reads. Traces of Nextera adapters were clipped from PE1 and PE2 100mer reads using the FASTX toolkit (Hannon Lab, CSHL). Reads greater than 15 nucleotides in length were retained. Additionally, reads with 50% or more bases below a base quality threshold of Q30 were dropped from subsequent analysis. Reference sequences with 10 bp genomic flanks were indexed using the Burrows-Wheeler Aligner (BWA) IS linear time algorithm 33 and reads were aligned using the BWA aligner. Reads with mapping quality greater than zero were retained. Overlapping alignments of paired end reads due to short inserts were resolved in order to avoid double counting of coverage and/or mutations observed in a single fragment. In order to minimize alignment ambiguity in the presence of mutations (including indels), the GATK Toolkit 34 was used to realign pooled cohorts mapping to a given locus. Mutations (base substitutions, insertions and deletions) were assessed using a combination of Samtools 35 and Annovar 36 (indel quantification and annotation), NGSUtils/BAMutils software suite 37 (total mutations per position), and custom scripts. Mutation frequencies were adjusted for sample purity (see next section) and per base substitution, insertion, and deletion frequencies were determined. Significance of overall mutation rates across 10 bp flanking the target locus was assessed using the Wilcoxon rank sum test comparing control and sgTarget sample events. Positional enrichment for mutation frequency compared to control samples was assessed using the conditional maximum likelihood odds ratio estimate (Fisher's exact test) and was mean centred and scaled (z-scores) across a 10 bp flank on either side of the PAM sequence in each sample. A number of other utilities/tools were used to enable various parts of the analysis, including: BEDTools 38 , the Integrated Genome Viewer (IGV) 39 , and Picard (http://broadinstitute.github.io/picard). Statistical analyses and sequence enrichment plots were implemented in R (http://www.R-project.org). Illumina MiSeq sequence data sets have been deposited into the NCBI repository under BioProjectID PRJNA256245. Tumour purity correction. Lung lobe and microdissected tumour genomic DNA was used to perform real-time PCR based analysis to detect the relative levels of the un-recombined Kras LSL-G12D allele (from non-tumour tissue) using forward primer: 59-CTCTTGCCTACGCCACCAGCTC-39 and reverse primer: 59-AGCTA GCCACCATGGCTTGAGTAAGTCTGCA-39. To correct for DNA loading of each sample, we amplified the chr5 10054507-10054621 region using forward primer: 59-GAAGAAATTAGAGGGCATGCTTC-39 and reverse primer: 59-CTTCTCC CAGTGACCTTATGTA-39. Real-time PCR reactions were performed using KAPA Fast SYBR master mix in a Roche LightCycler Real-Time PCR instrument. To calculate percent purity we performed the following calculations for each sample: DCp tumorX 5 Cp Chr5 2 Cp KrasLSL-G12D/1 to normalize for sample loading followed by 1/DDCp 5 1/(DCp tumorX 2 DCp LungControl ) for each sample to compare relative purity to lung tissue from Kras LSL-G12D/1 animals that were not infected with Cre. To validate the assay, we generated mouse embryonic fibroblasts from Kras LSL-G12D/1 mice treated with Cre recombinase (or control FlpO recombinase). Purity values are reported in Supplementary Table 3 . Statistics. P values were determined by Student's t-test for all measurements of tumour burden and IHC quantifications except for contingency tables, in which Fisher's exact test or Chi-square test were used. All error bars denote s.e.m.
